Improving therapies. Saving lives.
Our Mission
Evaluate promising therapeutic approaches in multi-institutional clinical trials to improve the outcomes of blood and bone marrow transplantation and other cellular therapies for patients facing life-threatening blood disorders.
BMT CTN by the Numbers
- 125+
- Sites
- 50+
- Clinical Studies Launched
- 15,500+
- Patients Enrolled
- 520,000+
- Biospecimens Collected
- 130+
- Papers Published
BMT CTN at a Glance for…
- Investigators or Research Staff...
- Conducts paradigm changing research addressing important issues in transplantation and cellular therapy
- >50 studies opened at >150 transplant centers in 39 US states since inception in 2001
- Opportunities for investigators at all levels
- Patients or Caregivers...
- Improves care and outcomes for patients needing transplantation and other cellular therapies
- Conducts studies to evolve treatment options for patients with a wide variety of diseases
- Provides access to clinical research studies for patients at centers across the US
- Partners...
- Led by global experts in transplantation and cellular therapy who work together to achieve common goals
- Proven track record in protocol development, accrual and results dissemination
- Network includes the largest US transplant and cell therapy centers
Number of Patients Enrolled on BMT CTN Studies
The BMT CTN is funded by the National Heart, Lung, and Blood Institute (NHLBI) and the National Cancer Institute (NCI), both parts of NIH (National Institutes of Health) with grants to:
Data and Coordinating Center: (U10 HL069294 and U24 HL138660), and to the Core and Consortia Sites: UG1 HL69246, UG1 HL 69249, UG1 HL 69254, UG1 HL69274, UG1 HL69278, UG1 HL69286, UG1 HL69290, UG1 HL69291, UG1 HL69301, UG1 HL69310, UG1 HL69315, UG1 HL69330, UG1 HL108945, UG1 HL108987, UG1 HL109137, UG1 HL109322, UG1 HL109526, UG1 HL138641, UG1 HL138645, and UG1 HL138658